VolitionRX Limited (NYSEAMERICAN:VNRX) Stock Short Interest Drops 54.8%

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 1,004,963 shares, a decrease of 54.8% from the August 31st total of 2,224,050 shares. Based on an average daily trading volume, of 1,733,578 shares, the days-to-cover ratio is presently 0.6 days. Approximately 7.9% of the company’s stock are short sold.

VolitionRX Trading Up 1.3%

NYSEAMERICAN:VNRX traded up $0.00 during trading hours on Tuesday, reaching $0.26. 2,103,145 shares of the stock were exchanged, compared to its average volume of 3,124,353. VolitionRX has a twelve month low of $0.23 and a twelve month high of $14.80. The firm has a 50 day moving average of $0.51 and a 200 day moving average of $1.77.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings data on Thursday, August 13th. The medical research company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.41 million. As a group, analysts expect that VolitionRX will post -1.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VNRX has been the topic of several research reports. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Maxim Group reiterated a “buy” rating and set a $4.00 target price on shares of VolitionRX in a report on Thursday, June 18th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.00.

VolitionRX Company Profile

VolitionRx Limited is a life sciences company developing blood-based diagnostic tests for cancer and other diseases. The company’s technology is based on nucleosomes, fragments of DNA and associated proteins released into the bloodstream during cell death, which may provide information useful for disease detection, monitoring and treatment decisions.

VolitionRx’s product development activities include its Nu.Q technology platform and Nu.Q Vet, a suite of veterinary cancer screening and monitoring tests designed for use in dogs and other companion animals.